Replimune Group, Inc.
REPL · NASDAQ
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.61 | -0.29 | -0.18 | -0.26 |
| FCF Yield | -25.33% | -37.14% | -12.68% | -9.53% |
| EV / EBITDA | -2.96 | -2.27 | -5.49 | -7.11 |
| Quality | ||||
| ROIC | -53.07% | -52.04% | -28.72% | -26.64% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.78 | 0.86 | 0.73 | 0.70 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | -100.00% |
| Free Cash Flow Growth | -4.09% | -46.66% | -54.20% | -32.51% |
| Safety | ||||
| Net Debt / EBITDA | 0.14 | -0.01 | 0.50 | 0.64 |
| Interest Coverage | -33.15 | -35.25 | -42.57 | -54.65 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | -297.74 |